📰 BloombergBloombergCodex · 实盘不做把握 8/10
北京时间·🕒 发布 08-03 19:50:52时区推断·⟳ 抓取 08-03 20:11:52·⚡ 决策 08-04 09:59:05 +13h47m·84.6 天前
Curium拟以约80亿美元收购Lantheus
Curium拟支付每股102.50美元现金及最高12美元CVR收购Lantheus，交易价值约80亿美元。
📄 原文Bloomberg↗ 原文
Closely held nuclear medicine company Curium has struck a deal to take Lantheus Holdings Inc. private in a transaction…
不做 Lantheus Holdings（LNTH.US）
同一Curium收购Lantheus催化已于已处理消息库命中，当前不重复出卡。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 high · price-in 风险 high ↗
消息传播链
- Bloomberg报道Curium以约80亿美元收购Lantheus，含每股102.50美元现金和最高12美元CVR。
- 2026-08-04 01:42 UTC其它search_processed_events非一手已处理事件命中：Curium拟以每股102.50美元现金加最高12美元CVR收购Lantheus。
关键理由
- Curium拟支付每股102.50美元现金及最高12美元CVR收购Lantheus，交易价值约80亿美元。
主要风险
- 同一收购催化已在近72小时处理，本条为重复转述，不应重复推卡。
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,169 字
Closely held nuclear medicine company Curium has struck a deal to take Lantheus Holdings Inc. private in a transaction worth about $8 billion.
The Capvest Partners-backed firm is paying about $102.50 per share upfront and an additional $12 per Lantheus share in contingent value right, which confirms an earlier Bloomberg News report. This represents a premium of 21% to Lantheus shares before news of a deal broke.
Contingent value rights are a promise to give shareholders more money in a merger if a future goal happens.
Curium was valued at about $7 billion last year, when CapVest raised money for a continuation vehicle for the Bedford, Massachusetts company.
Lantheus had been weighing a sale after getting a takeover offer from Curium, Bloomberg reported in May.
Lantheus generates most of its revenue selling Pylarify, a radioactive imaging agent used to help determine whether prostate cancer has spread to other parts of the body. Curium makes radioactive tracers that are used in nuclear medicine to help diagnose cancer and heart, bone and brain diseases.
The companies announced a licensing and distribution agreement in the European market in 2023.
The Capvest Partners-backed firm is paying about $102.50 per share upfront and an additional $12 per Lantheus share in contingent value right, which confirms an earlier Bloomberg News report. This represents a premium of 21% to Lantheus shares before news of a deal broke.
Contingent value rights are a promise to give shareholders more money in a merger if a future goal happens.
Curium was valued at about $7 billion last year, when CapVest raised money for a continuation vehicle for the Bedford, Massachusetts company.
Lantheus had been weighing a sale after getting a takeover offer from Curium, Bloomberg reported in May.
Lantheus generates most of its revenue selling Pylarify, a radioactive imaging agent used to help determine whether prostate cancer has spread to other parts of the body. Curium makes radioactive tracers that are used in nuclear medicine to help diagnose cancer and heart, bone and brain diseases.
The companies announced a licensing and distribution agreement in the European market in 2023.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。